1. Home
  2. IPO
  • Astonea Labs Ltd IPO
Astonea Labs Ltd logo

Astonea Labs IPO

  • Status: Closed
  • RHP:
  • ₹ 128,000 / 1000 shares

    Minimum Investment

IPO Details

  • Open Date

    27 May 2025

  • Close Date

    29 May 2025

  • Listing Date

    03 Jun 2025

  • IPO Price Range

    ₹ 128 to ₹135

  • IPO Size

    ₹ 37.67 Cr

  • Listing Exchange

    BSE SME

Open Free Demat Account

+91
Resend OTP

By proceeding, you agree to all T&C*

hero_form
Timeline Subscription Status Financials SWOT FAQ Contacts

IPO Timeline

Astonea Labs IPO Subscription Status

Last Updated: 29 May 2025 6:53 PM by 5paisa

Astonea Labs Ltd is launching a ₹37.67 crore IPO. The company specializes in contract manufacturing of pharmaceutical and cosmetic products for domestic and international markets. Its portfolio includes antibiotics, anti-cold medicines, and skincare, haircare, and dental products under brands like "Glow Up" and "Regero," with "Avicel" upcoming. Astonea also trades in packaging and raw materials, adhering to industry standards, and exports to countries like Iraq and Yemen.

Established in: 2017
Managing Director: Mr. Ashish Gulati

Peers

Beta Drugs Limited
 

Objectives

Registration expenses in Bolivia, South America 
Purchase and installation plant & machinery for export-quality ointment production (2nd floor, existing premises)
Advertising, marketing & brand building
Hardware and software procurement
Working capital funding
General corporate purposes
 

Astonea Labs IPO Size

Types Size
Total IPO Size ₹37.67 Cr.
Offer For Sale -
Fresh Issue ₹37.67 Cr.

 

 Astonea Labs IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 1000 128,000
Retail (Max) 1 1000 128,000
HNI (Min) 2 2000 256,000

Astonea Labs IPO Reservation

Investors Category Subscription (times) Shares Offered Shares bid for Total Amount (Cr.)*
QIB 0.70 13,20,000 9,27,000 12.515
NII (HNI) 5.60 3,99,000 22,33,000 30.146
Retail 1.69 9,27,000 15,67,000 21.155
Total** 1.79 26,46,000 47,27,000 63.815

 

*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.

Profit and Loss

Balance Sheet

Particulars (in Rs. Crores) FY22 FY23 FY24
Revenue 30.17 67.26 80.29
EBITDA 5.65 7.05 11.71
PAT 0.25 0.67 3.81
Particulars (in Rs. Crores)] FY22 FY23 FY24
Total Assets 52.91 64.28 80.89
Share Capital 4.00 4.00 7.60
Total Borrowings 29.52 35.99 42.40
Particulars (in Rs. Crores FY22 FY23 FY24
Net Cash Generated From / (used in) operating activities -4.93 -1.05 4.05
Net Cash Generated From / (used in) investing activities -3.31 -3.08 -7.18
Net Cash Generated From / (used in) financing activities 8.17 4.14 3.45
Net Increase (Decrease) In Cash And Cash Equivalents -0.07 0.01 0.32


Strengths

1.Strong marketing and distribution network supporting domestic and export operations.
2. Experienced management team with deep industry knowledge.
3. Diverse and expanding product portfolio across pharma and cosmetics.
4. High-quality, innovative products offering a competitive edge in niche segments.
 

Weaknesses

1. Need for substantial funding to scale operations nationally.
2. Limited market share and presence in select segments.
3. Dependence on industry trends and external competition.
4. Exposure to pricing pressures from established global and local players.
 

Opportunities

1. Rising consumer preference for innovative and effective formulations.
2. Expanding demand in emerging markets and increased export potential.
3. Growing e-commerce channels enabling broader market penetration.
4. Increasing awareness around personal care and wellness driving demand.
 

Threats

1. Regulatory changes and shifting government policies.
2. Volatility in raw material prices affecting margins.
3. Evolving consumer preferences and demand patterns.
4. Competitive intensity and frequent market entries and exits.
 

1. Astonea Labs has shown strong financial growth, with revenue rising from ₹30.17 Cr in FY22 to ₹80.29 Cr in FY24.
2. The company operates in fast-growing pharma and cosmetics sectors with strong industry tailwinds.
3. Its experienced leadership and broad product range position it well for long-term scalability.
4. IPO funds will support manufacturing expansion, brand building, and export growth, boosting competitiveness.
 

1. India’s pharma and CMO sectors are growing rapidly, driven by global demand and cost efficiency.
2. The cosmetics market is expanding steadily, fueled by rising incomes and personal care awareness.
3. Astonea Labs is well-placed with its diverse portfolio and expertise in contract manufacturing.
4. IPO funding will support capacity expansion, brand growth, and international market reach.
 

Will You Apply for Astonea Labs IPO?

Yes No Maybe

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
Resend OTP

By proceeding, you agree to all T&C*

footer_form

FAQs

Astonea Labs IPO opens from 27 May 2025 to 29 May 2025.
 

The size of Astonea Labs IPO is ₹37.67 Cr.
 

The price of Astonea Labs IPO is fixed at ₹128 to ₹135  per share. 
 

To apply for Astonea Labs IPO, follow the steps given below:

●    Login to your 5paisa account and select the issue in the current IPO section    
●    Enter the number of lots and the price at which you wish to apply for the Astonea Labs  IPO.    
●    Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.    

You will receive a mandate notification to block funds in your UPI app.
 

The minimum lot size of Astonea Labs IPO is 1,000 shares and the investment required is ₹128,000.

The share allotment date of Astonea Labs IPO is 30 May 2025
 

The Astonea Labs IPO will likely be listed on 3 June 2025.

Oneview Corporate Advisors Pvt. Ltd. is the book running lead manager for Astonea Labs IPO.
 

Astonea Labs plans to utilise the raised capital from the IPO for:

  • Registration expenses in Bolivia, South America 
  • Purchase and installation plant & machinery for export-quality ointment production (2nd floor, existing premises)
  • Advertising, marketing & brand building
  • Hardware and software procurement
  • Working capital funding
  • General corporate purposes